Oral cyclophosphamide showed no clear difference in treatment failure compared with prednisone or placebo (low certainty).
Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).
It is very uncertain whether oral cyclophosphamide changes adverse events: hypertension with seizures compared with prednisone or placebo (very low certainty).
Summary of findings: Tripterygium wilfordii Hook F showed no clear difference in complete remission ( compared with prednisone (low certainty).
Summary of findings: Tripterygium wilfordii Hook F showed no clear difference in partial remission ( compared with prednisone (low certainty).
Summary of findings: Tripterygium wilfordii Hook F showed no clear difference in complete or partial remission ( compared with prednisone (low certainty).
Antiviral prophylaxis leads to lower CMV disease: all symptomatic CMV disease compared with placebo or no treatment (high certainty).
Ganciclovir showed no clear difference in death due to CMV disease compared with aciclovir (moderate certainty).
Ganciclovir showed no clear difference in all‐cause death compared with aciclovir (moderate certainty).
Ganciclovir showed no clear difference in acute rejection compared with aciclovir (high certainty).
Ganciclovir showed no clear difference in graft loss compared with aciclovir (moderate certainty).
Ganciclovir showed no clear difference in opportunistic infections: other viral infections compared with aciclovir (moderate certainty).
Ganciclovir may leads to higher leucopenia compared with aciclovir (low certainty).
Ganciclovir showed no clear difference in kidney dysfunction compared with aciclovir (moderate certainty).
Valaciclovir showed no clear difference in CMV disease compared with ganciclovir or valganciclovir (low certainty).
Valaciclovir showed no clear difference in all‐cause death compared with ganciclovir or valganciclovir (low certainty).
Valaciclovir showed no clear difference in CMV infection compared with ganciclovir or valganciclovir (low certainty).
Antiviral prophylaxis probably leads to lower death due to CMV disease compared with placebo or no treatment (moderate certainty).
It is very uncertain whether valaciclovir changes acute rejection compared with ganciclovir or valganciclovir (very low certainty).
Valaciclovir showed no clear difference in graft loss compared with ganciclovir or valganciclovir (low certainty).